Pneumonia (Cytomegalovirus - HHV-5)

Overview

Plain-Language Overview

Pneumonia caused by Cytomegalovirus (CMV) is an infection that affects the lungs, which are part of the respiratory system. This condition occurs when the CMV virus, a member of the herpesvirus family, infects lung tissue, leading to inflammation and difficulty breathing. It mainly affects people with weakened immune systems, such as those with HIV/AIDS or organ transplant recipients. The infection can cause symptoms like cough, fever, and shortness of breath. Because the lungs are responsible for oxygen exchange, this infection can significantly impair breathing and oxygen delivery to the body.

Clinical Definition

Cytomegalovirus pneumonia is a form of viral pneumonia caused by the human herpesvirus 5 (HHV-5), commonly known as CMV. It primarily affects immunocompromised patients, including those with AIDS, transplant recipients, or patients on immunosuppressive therapy. The core pathology involves CMV replication in alveolar epithelial cells and endothelial cells, leading to interstitial pneumonitis with diffuse alveolar damage. Clinically, it presents with fever, nonproductive cough, dyspnea, and hypoxemia. Radiographically, it often shows bilateral interstitial infiltrates. The disease is significant due to its high morbidity and mortality in vulnerable populations and requires prompt diagnosis and management.

Inciting Event

Reactivation of latent CMV in lung tissue triggered by immunosuppression or systemic illness.
Primary CMV infection in neonates or immunocompromised hosts leading to viral dissemination to lungs.
Exposure to CMV-infected bodily fluids in transplant recipients or immunosuppressed individuals.

Latency Period

Symptom onset typically occurs weeks to months after immunosuppression or transplant.
In congenital infection, pneumonia may develop within the first few weeks of life.
Reactivation-related pneumonia usually manifests 1 to 3 months post-transplant.

Diagnostic Delay

Symptoms often mimic other causes of pneumonia leading to initial misdiagnosis as bacterial or fungal pneumonia.
Lack of specific clinical features and low suspicion in non-HIV immunosuppressed patients delays diagnosis.
Standard bacterial cultures are negative, and specialized tests like CMV PCR or viral culture are required but not always promptly performed.
Radiographic findings are nonspecific and can be confused with other opportunistic infections.

Patient Population

Immunocompromised adults, including those with HIV/AIDS or post-transplant patients, are most commonly affected.
Neonates and infants with congenital or perinatal CMV infection can develop severe pneumonia.
Elderly patients with weakened immune defenses are at increased risk for CMV lung disease.

Risk Factors

Immunosuppression due to HIV/AIDS or immunosuppressive therapy is the primary risk factor for CMV pneumonia.
Organ transplantation, especially lung or hematopoietic stem cell transplant, increases susceptibility to CMV reactivation.
Prolonged corticosteroid use impairs cellular immunity facilitating CMV lung infection.
Neonates and premature infants have immature immune systems predisposing to severe CMV disease.
Advanced age and chronic comorbidities like diabetes may increase risk of CMV pneumonia.

Clinical Presentation

Signs & Symptoms

Fever and nonproductive cough are common initial symptoms of CMV pneumonia.
Dyspnea and progressive respiratory distress develop as lung involvement worsens.
Fatigue and malaise reflect systemic viral infection.
Hypoxemia may cause cyanosis and altered mental status in severe cases.
Weight loss and anorexia can occur in chronic or severe infections.

History of Present Illness

Gradual onset of fever, nonproductive cough, and dyspnea over days to weeks.
Progressive hypoxemia and respiratory distress in severe cases.
Associated symptoms may include fatigue, malaise, and weight loss in chronic infection.
In transplant patients, symptoms often develop after recent immunosuppressive therapy intensification.

Past Medical History

HIV/AIDS or other immunodeficiency syndromes significantly increase risk.
Solid organ or hematopoietic stem cell transplantation with recent immunosuppressive treatment.
Use of corticosteroids or other immunosuppressants for autoimmune diseases or malignancies.
History of congenital CMV infection in neonates presenting with pneumonia.
Previous episodes of CMV viremia or retinitis may indicate systemic reactivation.

Family History

No direct heritable pattern is associated with CMV pneumonia as it is an infectious disease.
Family history of immunodeficiency syndromes may predispose to severe CMV disease.
Congenital CMV infection risk may be increased with maternal primary CMV infection during pregnancy.

Physical Exam Findings

Crackles and decreased breath sounds over affected lung fields are common in CMV pneumonia.
Tachypnea and use of accessory muscles may be observed in severe respiratory distress.
Hypoxemia may be evident with cyanosis or altered mental status in advanced cases.
Fever and signs of systemic illness such as malaise and lymphadenopathy can be present.
Dullness to percussion may be noted if consolidation or effusion develops.

Diagnostic Workup

Diagnostic Criteria

Diagnosis is established by detecting CMV DNA or antigens in respiratory specimens using polymerase chain reaction (PCR) or immunohistochemistry. Chest imaging typically reveals bilateral interstitial infiltrates consistent with viral pneumonia. Definitive diagnosis may require lung biopsy showing characteristic cytomegalic cells with intranuclear and intracytoplasmic inclusions. Clinical correlation with immunosuppression status and exclusion of other pathogens is essential.

Pathophysiology

Key Mechanisms

Latent reactivation of cytomegalovirus (CMV) in pulmonary tissue leads to direct cytopathic effects and alveolar epithelial cell damage.
Immune-mediated inflammation causes interstitial pneumonitis with infiltration of mononuclear cells and giant cells.
Endothelial cell infection by CMV results in microvascular injury and increased vascular permeability contributing to pulmonary edema.
CMV-induced immunosuppression facilitates secondary bacterial or fungal superinfections worsening lung injury.
Viral replication in alveolar macrophages impairs local immune responses and promotes persistent infection.

Involvement	Details
Organs	Lungs are the main organs affected, with viral infection causing interstitial pneumonia and impaired gas exchange.
Organs	Bone marrow is affected by antiviral drug toxicity, leading to cytopenias during treatment of CMV pneumonia.
Tissues	Pulmonary alveolar tissue is the primary site of inflammation and viral cytopathic effect in CMV pneumonia.
Tissues	Bronchial mucosa is involved in viral replication and contributes to airway inflammation and obstruction.
Cells	Alveolar macrophages are key in initial immune response and viral clearance in CMV pneumonia.
	Cytotoxic T lymphocytes target and kill infected cells to control cytomegalovirus replication.
	Epithelial cells of the respiratory tract serve as primary sites of viral replication and injury in CMV pneumonia.
Chemical Mediators	Interferon-gamma is critical for activating macrophages and enhancing antiviral immunity against cytomegalovirus.
	Tumor necrosis factor-alpha (TNF-α) contributes to inflammation and tissue damage in the lungs during infection.
	Interleukin-6 (IL-6) is elevated in systemic inflammatory response and correlates with disease severity in CMV pneumonia.

Treatments

Pharmacological Treatments

Ganciclovir
- Mechanism:
  - Inhibits viral DNA polymerase, preventing viral DNA synthesis in cytomegalovirus.
- Side effects:
  - Bone marrow suppression
  - Neutropenia
  - Renal toxicity
- Clinical role:
  - First-line
Valganciclovir
- Mechanism:
  - Oral prodrug of ganciclovir that inhibits cytomegalovirus DNA polymerase.
- Side effects:
  - Bone marrow suppression
  - Neutropenia
  - Gastrointestinal upset
- Clinical role:
  - First-line
Foscarnet
- Mechanism:
  - Directly inhibits viral DNA polymerase by binding to the pyrophosphate binding site, effective against ganciclovir-resistant strains.
- Side effects:
  - Nephrotoxicity
  - Electrolyte imbalances
  - Seizures
- Clinical role:
  - Second-line
Cidofovir
- Mechanism:
  - Inhibits viral DNA polymerase and is used for resistant cytomegalovirus infections.
- Side effects:
  - Nephrotoxicity
  - Neutropenia
  - Ocular hypotony
- Clinical role:
  - Second-line

Non-pharmacological Treatments

Supportive oxygen therapy to maintain adequate oxygenation in patients with CMV pneumonia.
Mechanical ventilation in cases of respiratory failure due to severe cytomegalovirus lung involvement.
Regular monitoring of renal function and blood counts during antiviral therapy to manage toxicity.

Prevention

Pharmacological Prevention

Ganciclovir or valganciclovir prophylaxis in high-risk immunocompromised patients prevents CMV disease.
CMV-specific immunoglobulin may be used adjunctively in transplant recipients.
Preemptive antiviral therapy guided by CMV viral load monitoring reduces progression to pneumonia.

Non-pharmacological Prevention

Screening transplant donors and recipients for CMV serostatus to guide prophylaxis.
Strict infection control practices in healthcare settings to prevent CMV transmission.
Minimizing immunosuppression when possible to reduce risk of CMV reactivation.

Outcome & Complications

Complications

Respiratory failure requiring mechanical ventilation is a life-threatening complication.
Secondary bacterial pneumonia can supervene due to impaired lung defenses.
Disseminated CMV infection involving the gastrointestinal tract, retina, or CNS may occur.
Pulmonary fibrosis may develop after severe or prolonged infection.

Short-term Sequelae	Long-term Sequelae
Hypoxemic respiratory failure necessitating intensive care support. Prolonged hospitalization due to slow clinical improvement. Superimposed bacterial infections complicating recovery.	Chronic pulmonary fibrosis leading to restrictive lung disease and reduced lung function. Persistent immunosuppression increasing risk for recurrent infections. Bronchiectasis may develop secondary to lung tissue damage.

Differential Diagnoses

Pneumonia (Cytomegalovirus - HHV-5) versus Pneumocystis jirovecii pneumonia (PJP)

Pneumonia (Cytomegalovirus - HHV-5)	Pneumocystis jirovecii pneumonia (PJP)
Occurs in immunocompromised hosts but not specifically linked to CD4+ T cell depletion	Occurs primarily in patients with CD4+ T cell counts <200/μL, especially HIV/AIDS
Diffuse bilateral interstitial infiltrates often with nodular or patchy consolidation	Diffuse bilateral ground-glass opacities with relative sparing of lung periphery
Detection of CMV DNA by PCR or viral inclusion bodies on lung biopsy	Silver stain or immunofluorescence of induced sputum or BAL showing cysts

Pneumonia (Cytomegalovirus - HHV-5) versus Bacterial pneumonia (e.g., Streptococcus pneumoniae)

Pneumonia (Cytomegalovirus - HHV-5)	Bacterial pneumonia (e.g., Streptococcus pneumoniae)
Caused by intracellular DNA virus Cytomegalovirus (HHV-5)	Commonly caused by extracellular encapsulated bacteria like Streptococcus pneumoniae
Often has a subacute or insidious onset with systemic symptoms and diffuse interstitial infiltrates	Usually presents with acute onset of high fever, productive cough, and lobar consolidation
Requires antiviral therapy such as ganciclovir or valganciclovir	Responds rapidly to beta-lactam antibiotics

Pneumonia (Cytomegalovirus - HHV-5) versus Influenza virus pneumonia

Pneumonia (Cytomegalovirus - HHV-5)	Influenza virus pneumonia
Can occur in immunocompromised patients without seasonal pattern	Often occurs during seasonal influenza outbreaks with recent contact or community spread
Shows diffuse interstitial infiltrates with possible nodular lesions	Shows bilateral patchy ground-glass opacities and consolidations often with rapid progression
Positive CMV PCR or viral culture from bronchoalveolar lavage	Positive rapid influenza antigen test or PCR from respiratory samples

Pneumonia (Cytomegalovirus - HHV-5) versus Tuberculosis (Mycobacterium tuberculosis)

Pneumonia (Cytomegalovirus - HHV-5)	Tuberculosis (Mycobacterium tuberculosis)
Shows diffuse interstitial infiltrates without cavitation	Classically shows upper lobe cavitary lesions and nodular infiltrates
Negative acid-fast stain; positive CMV PCR or viral inclusions	Positive acid-fast bacilli stain and culture from sputum or BAL
Subacute systemic symptoms without classic tuberculosis constitutional signs	Chronic symptoms with night sweats, weight loss, and hemoptysis

Pneumonia (Cytomegalovirus - HHV-5) versus Aspergillus pneumonia

Pneumonia (Cytomegalovirus - HHV-5)	Aspergillus pneumonia
Occurs in T-cell immunosuppressed patients such as transplant recipients	Occurs mainly in neutropenic patients or those with prolonged corticosteroid use
Shows diffuse interstitial infiltrates without halo sign	Shows halo sign or air crescent sign on CT scan
Positive CMV PCR or viral inclusions on histology	Positive galactomannan antigen or culture for Aspergillus species